<DOC>
	<DOCNO>NCT00803010</DOCNO>
	<brief_summary>The purpose research compare effectiveness Tacrolimus Rapamycin Tacrolimus Methotrexate prevention severe graft-versus-host-disease . Graft-versus-host-disease ( GVHD ) risk associate allogeneic hematopoietic cell transplant ( HCT ) . An allogeneic hematopoietic cell transplant transplant use bone marrow blood cell come someone patient ( donor ) .</brief_summary>
	<brief_title>Graft-Versus-Host Disease ( GVHD ) Prophylaxis After Allogeneic Peripheral Blood Hematopoietic Cell Transplantation</brief_title>
	<detailed_description>All drug use study use prevention graft-versus-host-disease allogeneic hematopoietic cell transplant . Tacrolimus Methotrexate use combination currently use standard care prevention graft-versus-host-disease allogeneic hematopoietic cell transplant . Tacrolimus Rapamycin new combination test see would better Tacrolimus Methotrexate .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Age ≥ 16 ≤ 70 Signed inform consent Adequate vital organ function No active infection , asymptomatic infection well control antibiotic HIV negative ELISA RTPCR [ ELISA positive RTPCR negative , ELISA consider false positive ] Hepatitis B C negative serology RTPCR Performance status : Karnofsky Performance Status Score ≥ 60 % . Those Sorror 's comorbidity factor score &gt; 3 2 Sorror 's factor composite score ≥ 3</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Acute Graft Versus Host Disease ( aGVHD )</keyword>
	<keyword>GVHD</keyword>
	<keyword>graft-versus-host disease</keyword>
	<keyword>tacrolimus</keyword>
	<keyword>sirolimus</keyword>
	<keyword>methotrexate</keyword>
	<keyword>combination therapy</keyword>
	<keyword>GVHD prophylaxis</keyword>
</DOC>